Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10472081 | 0.85 | ALDH1A1 (0.54) | HSD17B10NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5207857 | 0.81 | ALDH1A1 (0.56) | RAB9AHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL5474706 | 0.81 | ALDH1A1 (0.56) | RAB9AHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL13994594 | 0.79 | HDAC3 (0.69) | HSD17B10NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL4687017 | 0.77 | HSD17B10 (0.64) | HSD17B10NPC1RAB9APOLBMAOA | |
| SCHEMBL4687025 | 0.77 | HSD17B10 (0.64) | HSD17B10NPC1RAB9APOLBMAOA | |
| SCHEMBL4687023 | 0.77 | HSD17B10 (0.64) | HSD17B10NPC1RAB9APOLBMAOA | |
| Butyramide SCHEMBL28632307 | 0.77 | HSD17B10 (0.54) | HSD17B10NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL9732699 | 0.76 | LMNA (0.56) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL4255261 | 0.76 | SMN1; SMN2 (0.47) | HSD17B10NPC1RAB9AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| US-7199136-B2 | 1,4-dihydro-1,4-diphenylpyridine derivatives | BAYER HEALTHCARE AG (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | BAYER HEALTHCARE AG | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | SERPINB1, ELANE, MPO | HSD17B10 2446/4885NPC1 1221/4885RAB9A 2353/4885 |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | SERPINB1, ELANE, MPO | HSD17B10 1774/4885NPC1 1295/4885RAB9A 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.